Siplizumab

Tax included
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells.
MedChemExpress 
HY-P99904

Data sheet

Size
Multiple sizes
Reactivity
CD2
Application
COVID-19-immunoregulation
CAS
288392-69-8